Skip to main content

Advertisement

SpringerLink
Log in

Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis

  • Original Article
  • Published:
Modern Rheumatology

Abstract

We conducted a 1-year prospective study to clarify differences between the Health Assessment Questionnaire disability index (HAQ-DI) and the modified HAQ (mHAQ) score among rheumatoid arthritis (RA) patients treated with infliximab. A total of 87 patients were scheduled to receive infliximab infusion at a dose of 3 mg/kg at weeks 0, 2, and 6, and every 8 weeks thereafter for 54 weeks; all patients received a full examination at each infusion appointment. The 28-joint disease activity score (DAS28) and functional capability of each patient was assessed at each visit, using the HAQ-DI and the mHAQ score. A strong correlation was observed between the HAQ-DI and the mHAQ score at baseline (r = 0.892). Over the course of the treatment, the mean mHAQ score changed similarly to the HAQ-DI, but the mean HAQ-DI was significantly higher than the mean mHAQ score at each time-point (for the HAQ-DI vs. mHAQ score, baseline: 1.5 ± 0.7 vs. 0.9 ± 0.6, p < 0.0001; 6 weeks: 1.1 ± 0.7 vs. 0.6 ± 0.5, p < 0.0001; 30 weeks: 1.0 ± 0.7 vs. 0.6 ± 0.5, p < 0.0001; 54 weeks: 0.9 ± 0.7 vs. 0.6 ± 0.6, p = 0.0006). In the categories of “eating”, “reaching”, and “other activities”, the scores for several items excluded from the mHAQ score were significantly higher than those included in the mHAQ score over the year-long study period. We identified items contributing to significant differences between the HAQ-DI and the mHAQ score among RA patients treated with infliximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lipsky PE. Rheumatoid arthritis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 15th ed. NewYork: McGraw-Hill; 2001. p. 1928–37.

  2. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol. 2003;30:167–78.

    PubMed  Google Scholar 

  3. Pincus T, Summey JA, Soraci SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum. 1983;26:1346–53.

    Article  CAS  PubMed  Google Scholar 

  4. Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49:784–8.

    Article  PubMed  Google Scholar 

  5. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542–50.

    Article  CAS  PubMed  Google Scholar 

  6. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol. 2001;28:982–9.

    CAS  PubMed  Google Scholar 

  7. Uhlig T, Haavardsholm EA, Kvien TK. Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. Rheumatology. 2006;45:454–8.

    Article  CAS  PubMed  Google Scholar 

  8. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.

    Article  CAS  PubMed  Google Scholar 

  9. Ivashkiv LB. Cytokine expression and cell activation in inflammatory arthritis. Adv Immunol. 1996;63:337–76.

    Article  CAS  PubMed  Google Scholar 

  10. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.

    Article  CAS  PubMed  Google Scholar 

  11. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004;63:149–55.

    Article  CAS  PubMed  Google Scholar 

  12. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43.

    Article  CAS  PubMed  Google Scholar 

  13. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381–90.

    Article  CAS  PubMed  Google Scholar 

  14. Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27–35.

    Article  CAS  PubMed  Google Scholar 

  15. Kameda H, Sekiguchi N, Nagasawa H, Amano K, Takei H, Suzuki K, et al. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. Mod Rheumatol. 2006;16:381–8.

    Article  CAS  PubMed  Google Scholar 

  16. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28–32.

    Article  CAS  PubMed  Google Scholar 

  17. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol. 2008;18:146–52.

    Article  CAS  PubMed  Google Scholar 

  18. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol. 2008;18:447–54.

    Article  CAS  PubMed  Google Scholar 

  19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.

    Article  CAS  PubMed  Google Scholar 

  20. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 1999;26:743–5.

    PubMed  Google Scholar 

  21. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, Van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.

    Article  CAS  PubMed  Google Scholar 

  22. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol. 1993;20:557–60.

    CAS  PubMed  Google Scholar 

  23. Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54:702–10.

    Article  CAS  PubMed  Google Scholar 

  24. Nagasawa H, Kameda H, Sekiguchi N, Amano K, Takeuchi T. Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. Mod Rheumatol. 2009;19:166–72.

    Article  CAS  PubMed  Google Scholar 

  25. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051–65.

    Article  CAS  PubMed  Google Scholar 

  26. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 2000;43(3):506–14.

    Article  CAS  PubMed  Google Scholar 

  27. Wolfe F. Health status questionnaires. Rheum Dis Clin North Am. 1995;21:445–64.

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

This work was supported by grants from the Ministry of Health, Labor and Welfare (No. H19-Immunology-general-006). T.T. received an honorarium from Mitsubishi Tanabe Pharma Corporation. H.K. received an honorarium from Mitsubishi Tanabe Pharma Corporation. The other authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan

    Hayato Nagasawa, Naoya Sekiguchi, Koichi Amano & Tsutomu Takeuchi

  2. Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan

    Hideto Kameda & Tsutomu Takeuchi

Authors
  1. Hayato Nagasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideto Kameda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoya Sekiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koichi Amano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tsutomu Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hayato Nagasawa.

About this article

Cite this article

Nagasawa, H., Kameda, H., Sekiguchi, N. et al. Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. Mod Rheumatol 20, 337–342 (2010). https://doi.org/10.1007/s10165-010-0284-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-010-0284-8

Keywords

Search

Navigation